

E Magnus Ohman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5386659/publications.pdf>

Version: 2024-02-01

35
papers

7,663
citations

623699

14
h-index

395678

33
g-index

35
all docs

35
docs citations

35
times ranked

10079
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	1.6	3,378
2	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	2.8	2,558
3	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	27.0	683
4	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. <i>European Heart Journal</i> , 2009, 30, 1457-1466.	2.2	315
5	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet</i> , 2017, 389, 1799-1808.	13.7	174
6	Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the Targeted platelet Inhibition to Clarify the Optimal Strategy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 231-242.	1.0	110
7	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016, 182, 125-134.	2.7	108
8	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 162-171.	2.8	50
9	Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 443-454.	1.0	43
10	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2016, 67, 936-947.	2.8	35
11	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015, 170, 683-694.e3.	2.7	26
12	Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. <i>European Heart Journal</i> , 2016, 37, ehv611.	2.2	25
13	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 73.	6.1	22
14	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693.	2.2	18
15	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1289-1297.	2.8	15
16	Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. <i>Heart</i> , 2015, 101, 279-286.	2.9	14
17	Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes. <i>Stroke</i> , 2016, 47, 1135-1139.	2.0	10
18	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 680.	6.1	9

#	ARTICLE	IF	CITATIONS
19	Philanthropy for Science. <i>Circulation Research</i> , 2016, 119, 1057-1059.	4.5	8
20	Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 847-856.	3.0	8
21	Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the <sc>TRILOGY ACS</sc> Trial. <i>Clinical Cardiology</i> , 2016, 39, 329-337.	1.8	7
22	Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 430-437.	1.7	7
23	Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent) Tj ETQq1 1 0.7843146gBT / Overlock 10	1.7	6
24	Outcomes of bailout percutaneous ventricular assist device versus prophylactic strategy in patients undergoing nonemergent percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E501-E512.	1.7	6
25	Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the <sc>TRILOGY ACS</sc> Trial. <i>Clinical Cardiology</i> , 2016, 39, 497-506.	1.8	5
26	Understanding the patient experience of pain and discomfort during cardiac catheterization. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, E196-E200.	1.7	5
27	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. <i>Heart</i> , 2016, 102, 1221-1229.	2.9	3
28	Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>American Heart Journal</i> , 2016, 178, 55-64.	2.7	3
29	Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. <i>International Journal of Cardiology</i> , 2019, 291, 36-41.	1.7	3
30	Assessing Quality of Life and Medical Care in Chronic Angina: An Internet Survey. <i>Interactive Journal of Medical Research</i> , 2016, 5, e12.	1.4	3
31	Impact of Nonculprit Vessel Myocardial Perfusion on Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 266-275.	2.9	2
32	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1322-1329.	1.6	2
33	Logistical Challenges Associated With Implementing Precision Medicine—Reply. <i>JAMA Cardiology</i> , 2019, 4, 1301.	6.1	1
34	Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. <i>American Journal of Cardiology</i> , 2020, 125, 1280-1283.	1.6	1
35	Cholesterol Lowering and Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 268-270.	2.8	0